Skip to main content

Table 1 Clinical characteristics of eyes treated with PDT

From: Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration

Included eye

Patient characteristics

Lesion type

Pre-PDT BCVA (logMAR)

Disease duration (months)

Previous PDT sessions(n)

Previous anti-VEGF injections (n)

Pre-PDT RPE atrophy

Treatment methods

Spot size (μm)

Age (years)

Sex

DM

HTN

1

81

M

Y

N

CNV

1.00

132

1

8

Y

PDT + IVB

5900

2

52

F

N

N

CNV

0.80

1

0

0

Y

PDT + IVB

3500

3

82

F

N

N

CNV

0.92

108

4

1

Y

PDT + Dexamethasone + IVB

3600

4

66

M

Y

Y

PCV

0.49

16

2

3

Y

PDT + Dexamethasone + IVB

3700

5

84

M

N

N

CNV

0.49

48

5

7

Y

PDT + Dexamethasone + IVB

2900

6

79

F

N

Y

RAP

0.80

1

0

1

Y

PDT + Dexamethasone + IVB

4500

7

78

F

N

Y

PCV

1.30

20

2

7

N

PDT + IVB

5800

8

60

F

N

N

CNV

0.10

68

6

3

Y

PDT + IVB

4100

9

75

F

N

N

PCV

1.30

21

2

1

N

PDT + Dexamethasone + IVB

4900

10

73

M

Y

Y

PCV

0.30

18

1

1

N

PDT + Dexamethasone + IVB

5200

11

71

M

N

Y

PCV

1.30

48

3

1

Y

PDT + IVB

6400

12

65

M

N

N

CNV

0.80

8

0

1

N

PDT

5050

13

60

M

N

N

CNV

0.49

19

3

11

N

PDT + IVR

1900

14

68

F

N

N

RAP

0.00

12

1

1

Y

PDT + IVB

1400

15

62

M

N

Y

CNV

0.80

9

1

2

N

PDT + Dexamethasone + IVB

3200

16

64

M

N

Y

CNV

0.80

26

4

9

N

PDT + IVB

2700

17

52

M

N

N

CNV

0.20

4

1

1

Y

PDT + Dexamethasone + IVB

3200

18

28

M

N

N

CNV

N/A

1

0

1

Y

PDT + IVB

2600

19

50

F

N

N

PCV

0.00

1

0

0

N

PDT + IVR

4800

20

34

M

N

N

CNV

0.10

11

0

3

N

PDT

1900

21

67

M

N

N

PCV

0.70

8

0

9

N

PDT + IVB

3700

22

69

M

N

N

PCV

0.52

22

1

14

N

PDT

4000

23

74

M

N

N

PCV

0.52

17

0

14

N

PDT

1500

24

70

F

N

N

PCV

0.52

14

0

6

N

PDT

2800

25

70

F

N

N

PCV

0.82

14

0

8

N

PDT

3300

26

74

F

Y

Y

PCV

0.70

60

0

9

N

PDT

3700

27

67

F

N

N

CNV

0.10

24

0

9

N

PDT

2500

28

77

M

N

N

PCV

0.00

30

0

16

N

PDT

1500

29

77

M

N

N

CNV

0.70

3

0

10

N

PDT

4200

  1. BCVA best-corrected visual acuity, CNV choroidal neovascularisation, DM diabetes mellitus, F female, HTN hypertension, IVB intravitreal injection of bevacizumab, IVR intravitreal injection of ranibizumab, logMAR logarithm of the minimum angle of resolution, M male, N no, N/A not accessed, PCV polypoidal choroidal vasculopathy, PDT photodynamic therapy, RAP retinal angiomatous proliferation, RPE retinal pigment epithelium, VEGF vascular endothelial growth factor, Y yes